- COMMUNITY DENTISTRY
Introduction The Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) is responsible for the global pandemic of Coronavirus disease-2019 (COVID-19). Human-to-human transmission occurs mainly through the aerosolization of respiratory droplets. Improved antisepsis of human and non-human surfaces has been identified as a key feature of transmission reduction. Flavobac, a complex of soluble bioflavonoids and hydroxylated phenolic structures used in oral care products, has demonstrated efficacy to act against microorganisms. This study evaluated nasal and oral antiseptic formulations of FLAVOBAC for the virucidal activity against SARS-CoV-2.
Methodology FLAVOBAC nasal antiseptic formulations and FLAVOBAC oral rinse antiseptic formulations from 1-10% concentrations were assayed for virucidal efficacy against the SARS-CoV-2 virus. SARS-CoV-2 was exposed directly to the test compound for 60 seconds or 5 minutes. Compounds were then neutralized, and the surviving virus was quantified.
Results All concentrations of nasal antiseptics and oral rinse antiseptics evaluated completely inactivated the SARS-CoV-2 virus.
Conclusion Nasal and oral FLAVOBAC solutions are effective at inactivating the SARS-CoV-2 virus at a variety of concentrations after 60-second or 5-minute exposure times. The formulations tested have the potential to reduce the transmission of SARS-CoV-2 if used for nasal/oral decontamination, or surface decontamination in known or suspected cases of COVID-19.
Bioflavonoid; COVID-19; Flavobac, SARS-COV-2; Virucidal Activity.
Figures are shown in pdf document
| (read pdf) |